Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Ann Hematol
    March 2026
  1. GURER T, Gunay UB, Kilic B, Akkan Suzan A, et al
    Restless legs syndrome in chronic myeloid leukemia: an overlooked condition with a significant impact on health-related quality of life.
    Ann Hematol. 2026;105:190.
    >> Share

  2. HASSANI MA, Huang D, Gao Y, Zhang X, et al
    The novel ETV6::RARA fusion gene, identified in acute promyelocytic leukemia, is sensitive to invitro all-tans retinoic acid and arsenic trioxide administrations.
    Ann Hematol. 2026;105:178.
    >> Share

  3. LI Y, Fan Z, Wang LN, Tang YL, et al
    Incidence, clinical features and risk factors of interstitial pneumonia in children with acute lymphoblastic leukemia.
    Ann Hematol. 2026;105:180.
    >> Share

  4. MORELLI F, Linari S, Rapolla CM, Attanasio M, et al
    Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia.
    Ann Hematol. 2026;105:177.
    >> Share

  5. WANG Y, Xiao Y
    CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2026;105:179.
    >> Share

  6. PEI W, Zhang X, Du LA, Liu Z, et al
    Role of cystatin C in predicting the risk of hypermethotrexemia and kidney injury after high-dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.
    Ann Hematol. 2026;105:176.
    >> Share

  7. SUN Y, Qin S, Wang L, Yi H, et al
    The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.
    Ann Hematol. 2026;105:168.
    >> Share

    February 2026
  8. ONCUL Y, Akyay A, Macit B, Ozgen U, et al
    Treatment Outcomes and Factors Affecting Survival in Pediatric Acute Myeloid Leukemia.
    Ann Hematol. 2026;105:141.
    >> Share

  9. PAN Y, Shen Y, Miao S, Yao C, et al
    The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2026;105:139.
    >> Share

  10. ATEF B, El-Ashwah S, Saleh LM, Gawish H, et al
    Potential utility of PPARgamma agonists in targeting chronic myeloid leukemia stem cells.
    Ann Hematol. 2026;105:136.
    >> Share

  11. EFENDI ERDEM E, Cecener G, Unal U, Tezcan Unlu H, et al
    Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.
    Ann Hematol. 2026;105:138.
    >> Share

  12. SHELIKHOVA L, Ilyushina M, Khismatullina R, Balashov D, et al
    Long-term outcome of children with acute lymphoblastic leukemia after hematopoietic stem cell transplantation based on ex-vivo alpha-beta T cell depletion.
    Ann Hematol. 2026;105:135.
    >> Share

  13. SHIMOMURA Y, Komukai S, Kitamura T, Sobue T, et al
    The optimal conditioning intensity of stem cell transplantation for acute myeloid leukemia in complete remission.
    Ann Hematol. 2026;105:124.
    >> Share

  14. MAZZARELLA R, Cicconi L, Perrone S, Divona MD, et al
    Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia.
    Ann Hematol. 2026;105:121.
    >> Share

  15. NG JY, Gullapalli V, Othman J, Talaulikar D, et al
    Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review.
    Ann Hematol. 2026;105:120.
    >> Share

  16. AKIMOTO M, Tachibana T, Tanaka M, Izumi A, et al
    Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.
    Ann Hematol. 2026;105:118.
    >> Share

  17. JI Q, Jiang X, Li X, Cao C, et al
    Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.
    Ann Hematol. 2026;105:119.
    >> Share

  18. BUDZISZEWSKA BK, Lomiak M, Barankiewicz J, Patkowska E, et al
    Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.
    Ann Hematol. 2026;105:114.
    >> Share

  19. MA Y, Cheng Y, Sun Y, Zhu X, et al
    Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective stu
    Ann Hematol. 2026;105:113.
    >> Share

  20. JIANG B, Li J, Liu L, Du X, et al
    Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
    Ann Hematol. 2026;105:108.
    >> Share

  21. ZHANG T, Liu D, Ren F, Hao J, et al
    Chronic lymphocytic leukemia with IGH/BCL2 fusion and clonal heterogeneity: phenotypic and molecular profiling analysis of a rare case.
    Ann Hematol. 2026;105:105.
    >> Share

  22. YUAN R, Xie Y, Miron PM, Higgins AW, et al
    Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.
    Ann Hematol. 2026;105:99.
    >> Share

  23. YOON JH, Lee JH, Yang DH, Cheong JW, et al
    Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance.
    Ann Hematol. 2026;105:91.
    >> Share

  24. GEORGI JA, Rollig C, Schetelig J, Thiede C, et al
    Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases.
    Ann Hematol. 2026;105:82.
    >> Share

  25. GEISSLER K, Mitterbauer-Hohendanner G, Jager R
    Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report.
    Ann Hematol. 2026;105:78.
    >> Share

  26. SUAREZ EU, Atencia CJ, Torres-Saavedra FA, Conejero N, et al
    The effects of the PHF6 gene mutation on myeloid neoplasms. A single-center cohort underpinned by a systematic review of literature.
    Ann Hematol. 2026;105:77.
    >> Share

  27. LU L, Liang Q, Yan Y, Tang Y, et al
    Dynamic changes in mortality risk factors for acute leukemia patients in the ICU and Post-ICU periods.
    Ann Hematol. 2026;105:76.
    >> Share

    January 2026
  28. CHEN L, Huang Y, Xu J, Huang S, et al
    Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report.
    Ann Hematol. 2026;105:67.
    >> Share

  29. LI Y, Liu Y, Yang Y, Liang Z, et al
    Hemophagocytic lymphohistiocytosis associated with extranodal NK/T cell lymphoma, nasal type or aggressive NK cell leukemia: a retrospective multicenter study of Jiangsu Cooperative Lymphoma Group (JCLG).
    Ann Hematol. 2026;105:68.
    >> Share

  30. MAMLEKAR H, Yadav S, Manogaran RS, Kashyap R, et al
    Audiological profile for assessment of sensorineural hearing loss in treatment naive chronic myeloid leukemia: impact of early TKI treatment on reversibility.
    Ann Hematol. 2026;105:65.
    >> Share

  31. DU L, Li F, Ding L, Song L, et al
    Risk factors for early mortality (within 6 weeks of diagnosis) in Chinese children with acute leukemia: a single-center retrospective cohort study.
    Ann Hematol. 2026;105:62.
    >> Share

  32. STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
    PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.
    Ann Hematol. 2026;105:49.
    >> Share

  33. PEREZ-LAMAS L, Manzanares M, Hernandez Boluda JC, Casado Montero LF, et al
    One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.
    Ann Hematol. 2026;105:40.
    >> Share

  34. JIANG R, Zhang Z, Liu Y, Qu W, et al
    KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis.
    Ann Hematol. 2026;105:42.
    >> Share

  35. WANG X, Mo W, Chen M, Sui J, et al
    Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis.
    Ann Hematol. 2026;105:41.
    >> Share

  36. ROBERT F, Badja C, Boushaki S, Degasperi A, et al
    BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.
    Ann Hematol. 2026;105:32.
    >> Share

  37. WU L, Liu P, Jiang B, Zhang X, et al
    Lycorine inhibits the proliferation of acute myeloid leukemia cells by upregulating the expression of THBS1.
    Ann Hematol. 2026;105:24.
    >> Share

  38. ZHANG ZX, Zhang L, Lu AD, Zhang LP, et al
    Paediatric blastic plasmacytoid dendritic cell neoplasm: a single-centre case series of 18 children and review of the literature.
    Ann Hematol. 2026;105:25.
    >> Share

  39. AL-SHIBLY R, Qassim N, Alfarsi K, AlShemmari S, et al
    Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review.
    Ann Hematol. 2026;105:30.
    >> Share

  40. LI Y, Shang Y, Liu K, Liu Y, et al
    Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study.
    Ann Hematol. 2026;105:23.
    >> Share

  41. ZHAO X, Ming X, Wu J, Zhu X, et al
    Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.
    Ann Hematol. 2026;105:20.
    >> Share

  42. BRUMMER C, Evert K, Keil F, Schmidt J, et al
    Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease.
    Ann Hematol. 2026;105:18.
    >> Share

  43. SCHENK T, Fabisch C, Ernst T, Ernst P, et al
    Ponatinib for CML patients in routine clinical practice: the PONDEROSA study.
    Ann Hematol. 2026;105:9.
    >> Share

  44. PATEL SA, Khedr S, Hutchinson L, Xie Y, et al
    Portraits of clonal hematopoiesis in DNMT3A/TET2/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia.
    Ann Hematol. 2026;105:15.
    >> Share

  45. ZHANG K, Ma X, Lu X, Ruan G, et al
    Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia.
    Ann Hematol. 2026;105:17.
    >> Share

  46. JIANG Y, Luo C, Yan H, Zhu L, et al
    Does differentiation syndrome in newly diagnosed acute promyelocytic leukemia warrant systemic antifungal therapy? A real-world clinical study.
    Ann Hematol. 2026;105:8.
    >> Share

  47. KARAKAS H, Tarcin G, Bayramoglu E, Turan H, et al
    Long-Term endocrine outcomes with special emphasis on the gonadal impact of acute lymphoblastic leukemia treatment in females.
    Ann Hematol. 2026;105:7.
    >> Share

  48. CEMAZAR L, Slajpah K, Gredelj Simec N, Podgornik H, et al
    A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL.
    Ann Hematol. 2026;105:5.
    >> Share

  49. JIANG B, Li J, Liu L, Du X, et al
    Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
    Ann Hematol. 2026;105:3.
    >> Share

  50. TARANTINI F, Contento C, Vigna E, Carluccio V, et al
    Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?
    Ann Hematol. 2026;105:1.
    >> Share

    December 2025
  51. LUO C, Zhang J, Huang X, Wu G, et al
    The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Ann Hematol. 2025 Dec 23. doi: 10.1007/s00277-025-06342.
    >> Share

  52. CHEN J, Li J, Wang Z, Huang Z, et al
    Intensified pegylated-asparaginase in consolidation therapy improved outcome of allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Dec 23. doi: 10.1007/s00277-025-06576.
    >> Share

  53. CHEN XT, Li Q, Zhao YQ, Fan SJ, et al
    Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world s
    Ann Hematol. 2025 Dec 18. doi: 10.1007/s00277-025-06653.
    >> Share

  54. ZHANG X, Zhao Y, Zhai W, Ma Q, et al
    Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome?.
    Ann Hematol. 2025;104:6463-6466.
    >> Share

  55. OSANNO L, Brocque L, Bourguignon L, Delpech C, et al
    Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.
    Ann Hematol. 2025;104:6327-6337.
    >> Share

  56. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
    Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland.
    Ann Hematol. 2025;104:6297-6304.
    >> Share

  57. KHALIFA IM
    Richter's transformation: status quo and quo vadis.
    Ann Hematol. 2025;104:6117-6130.
    >> Share

  58. SOHN C, Schafer-Eckart K, Wendelin K, Knop S, et al
    Early allogeneic stem cell transplantation after melphalan-induced aplasia leads to long-term survival in patients with primary refractory AML.
    Ann Hematol. 2025;104:6351-6358.
    >> Share

    November 2025
  59. YANG H, Xu Y, Zhang X, Wang Y, et al
    Serum miR-493-3p as a diagnostic biomarker and epigenetic regulator targeting DPY30 in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2025 Nov 18. doi: 10.1007/s00277-025-06681.
    >> Share

  60. DING W, Zhao J, Wang Z, Liu Y, et al
    Combination therapy based on venetoclax overcomes resistance to all-trans retinoic acid and arsenic trioxide in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.
    Ann Hematol. 2025 Nov 17. doi: 10.1007/s00277-025-06658.
    >> Share

  61. YU L, Jiang Q
    Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib.
    Ann Hematol. 2025 Nov 14. doi: 10.1007/s00277-025-06722.
    >> Share

  62. PRAJAPATI S, Patel M, Jyotishi C, Gupta R, et al
    Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential.
    Ann Hematol. 2025 Nov 7. doi: 10.1007/s00277-025-06710.
    >> Share

  63. HORNAK T, Zackova D, Mayer J
    Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia.
    Ann Hematol. 2025 Nov 5. doi: 10.1007/s00277-025-06703.
    >> Share

  64. WANG X, Liu C, Chen Y, Wang J, et al
    Relapse risk and outcome of discontinuing asparaginase in children with acute lymphoblastic leukemia.
    Ann Hematol. 2025 Nov 4. doi: 10.1007/s00277-025-06682.
    >> Share

  65. PEI W, Duan Y, Jin L, Yang X, et al
    Analysis of the clinical characteristics and prognostic factors of multicenter childhood Burkitt leukemia.
    Ann Hematol. 2025 Nov 3. doi: 10.1007/s00277-025-06672.
    >> Share

  66. BARTOLUCCI P, Gigli F, Tabanelli V, Valeriano A, et al
    BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy.
    Ann Hematol. 2025;104:6065-6069.
    >> Share

  67. HUANG W, Zhang F, Xie J, Wu C, et al
    A novel fusion gene of NUP98::CYP2F2P in myeloid neoplasm.
    Ann Hematol. 2025;104:6071-6074.
    >> Share

    October 2025
  68. SHI T, Cheng Z, Zhang Z, Jiang X, et al
    Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report.
    Ann Hematol. 2025 Oct 31. doi: 10.1007/s00277-025-06702.
    >> Share

  69. CAI Q, Xiao J, Weng C, Chen H, et al
    Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Oct 28. doi: 10.1007/s00277-025-06643.
    >> Share

  70. DIAMANTI C, Apolito V, Spadea M, Ceolin V, et al
    Bilateral facial palsy as presenting symptom of post-transplant relapsed acute myeloid leukemia treated with venetoclax: a case report and literature review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06647.
    >> Share

  71. YANG X, Zhang Z, Wu X, Yang X, et al
    A breast cancer patient developed gammadelta T-cell acute lymphoblastic leukemia after chemotherapy: a case report with literary review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06690.
    >> Share

  72. HUANG F, Yang K, Du J, Xuan L, et al
    Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06693.
    >> Share

  73. SUO T, Zhang J, Chen Y, Shi H, et al
    ResNet50 and Single-Cell Multi-Omics analysis identify key cellular and molecular features in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2025 Oct 23. doi: 10.1007/s00277-025-06675.
    >> Share

  74. ZHU L, Yi K, Zhou J, Hu G, et al
    Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review.
    Ann Hematol. 2025 Oct 22. doi: 10.1007/s00277-025-06680.
    >> Share

  75. ZHENG J, Wang Y, Li Z, Xiao P, et al
    Frequent TCR rearrangements in pediatric B-cell lymphoblastic acute leukemia: genomic and phenotypic features.
    Ann Hematol. 2025 Oct 20. doi: 10.1007/s00277-025-06687.
    >> Share

  76. KIM M, Song IC, Ahn SY, Jang HC, et al
    Cytogenetic risk-associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia.
    Ann Hematol. 2025 Oct 16. doi: 10.1007/s00277-025-06608.
    >> Share

  77. TANG S, Sheng L, Mu Q, Wang Y, et al
    NIPA1 depletion in tumor-associated macrophages via IGFBP2/EGFR attenuates acute myeloid leukemia progression and chemoresistance.
    Ann Hematol. 2025 Oct 14. doi: 10.1007/s00277-025-06688.
    >> Share

  78. QUINQUENEL A, Lepretre S, Dilhuydy MS, Bussot L, et al
    Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
    Ann Hematol. 2025 Oct 13. doi: 10.1007/s00277-025-06632.
    >> Share

  79. FAN H, Yang Y, Lu Y, Li J, et al
    Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic.
    Ann Hematol. 2025 Oct 11. doi: 10.1007/s00277-025-06639.
    >> Share

  80. DAI JT, He YY, Zhang YT, Zhang YJ, et al
    A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2025 Oct 10. doi: 10.1007/s00277-025-06656.
    >> Share

  81. ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
    Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.
    Ann Hematol. 2025 Oct 10. doi: 10.1007/s00277-025-06635.
    >> Share

  82. SONG F, Su L, Gao S
    Impact of FLT3 mutation on its intracellular localization and implications for anti-leukemia strategy.
    Ann Hematol. 2025 Oct 9. doi: 10.1007/s00277-025-06671.
    >> Share

  83. MAMLEKAR H, Gangadaran N, Yadav S, Kashyap R, et al
    Clinical profile and treatment outcomes in paediatric and adult acute promyelocytic leukemia: experience from a tertiary care centre in Northern India.
    Ann Hematol. 2025 Oct 7. doi: 10.1007/s00277-025-06646.
    >> Share

  84. YANG Y, Zhang X, Jiang N, Jin Y, et al
    Correction to: Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2025 Oct 1. doi: 10.1007/s00277-025-06665.
    >> Share

  85. YUAN X, Wu Y, Wang Y, Wu J, et al
    Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.
    Ann Hematol. 2025;104:5359-5369.
    >> Share

  86. MAQHUZU PN, Bocuk D, Boelz S, Hosseini SK, et al
    Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data.
    Ann Hematol. 2025;104:5237-5256.
    >> Share

  87. KONG J, Tian Z, Deng DX, Mo XD, et al
    Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report.
    Ann Hematol. 2025;104:5537-5541.
    >> Share

  88. YE F, Wang L, Qian Y, Deng W, et al
    Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.
    Ann Hematol. 2025;104:5507-5512.
    >> Share

    September 2025
  89. DAI Y, Ai Y, Sun S, Tang M, et al
    Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature.
    Ann Hematol. 2025 Sep 29. doi: 10.1007/s00277-025-06596.
    >> Share

  90. LI ST, Shi XM, Liu QJ, Tan YH, et al
    Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.
    Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06618.
    >> Share

  91. CHEN H, Chen M, Yang Z, Liao S, et al
    Identification of a novel PML exon 6 splice variant in atypical PML::RARalpha transcripts in acute promyelocytic leukemia.
    Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06613.
    >> Share

  92. LI J, Yuan Y, Niu FF, Wang Y, et al
    USP7 mutations are associated with adverse outcomes in pediatric T cell acute lymphoblastic leukemia and lymphoma.
    Ann Hematol. 2025 Sep 22. doi: 10.1007/s00277-025-06582.
    >> Share

  93. RANTI J, Jamalzadeh S, Makela E, Vikkula J, et al
    Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013-2022 in Finland.
    Ann Hematol. 2025 Sep 19. doi: 10.1007/s00277-025-06595.
    >> Share

  94. REN Z, De Moerloose B, Lammens T
    Prime-time for LncRNA signatures in acute myeloid leukemia?
    Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06616.
    >> Share

  95. AZZA E, Ben Othmen A, Bahri M, Hsasna R, et al
    T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults.
    Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06597.
    >> Share

  96. LOPEZ-FERNANDEZ E, de Linares-Fernandez S, Perez-Marfil MN, Vera-Goni JA, et al
    Correction to: Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.
    Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06603.
    >> Share

  97. WANG Y, Zong W, Fan J, Rong L, et al
    Rapidly progressing after umbilical cord blood transplantation in a boy with acute myeloid leukemia with KAT6A::EP300 fusion transcript.
    Ann Hematol. 2025 Sep 2. doi: 10.1007/s00277-025-06573.
    >> Share

  98. HUANG Y, Yang M, Hu J, Lang T, et al
    Transcriptome-based molecular subgroup identification and prognosis stratification in pediatric AML.
    Ann Hematol. 2025;104:4585-4603.
    >> Share

  99. GONG Y, Chai X, Liu X, Zhang Y, et al
    Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.
    Ann Hematol. 2025;104:4411-4427.
    >> Share

  100. JIANG J, Liu Y, Zeng Y, Lan Y, et al
    Survival analysis and prognosis model construction of elderly patients with acute promyelocyticleukemia: a retrospective study based on SEER database.
    Ann Hematol. 2025;104:4515-4524.
    >> Share

  101. DE OLIVEIRA MOTA F, de Toledo SRC, Tesser-Gamba F, Pires MGC, et al
    Challenges in accuracy in molecular genetic diagnosis of childhood AML: case series.
    Ann Hematol. 2025;104:4495-4503.
    >> Share

  102. QIAN B, Huang G, Cai X, Liu Y, et al
    Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients.
    Ann Hematol. 2025;104:4539-4547.
    >> Share

  103. JIMENEZ-VICENTE C, Beneit P, Cano-Ferri I, Merchan B, et al
    Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.
    Ann Hematol. 2025;104:4863-4871.
    >> Share

    August 2025
  104. SANZ-SOLAS A, Saiz-Rodriguez M, Simal SC, Rodriguez-Veiga R, et al
    Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes.
    Ann Hematol. 2025 Aug 30. doi: 10.1007/s00277-025-06543.
    >> Share

  105. LAZZAROTTO D, Testi AM, Fanin M, Mosna F, et al
    Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.
    Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06550.
    >> Share

  106. RAJENDRA KURUP A, Malcolmson J, Villani A, Kim RH, et al
    Rare germline ETV6 variant associated with thrombocytopenia and acute leukemia.
    Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06536.
    >> Share

  107. YANG Y, Zhang X, Jiang N, Jin Y, et al
    Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2025 Aug 26. doi: 10.1007/s00277-025-06535.
    >> Share

  108. GAO Q, Chen Y, Le S, Li N, et al
    Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death.
    Ann Hematol. 2025 Aug 12. doi: 10.1007/s00277-025-06528.
    >> Share

  109. LI H, Gu Y, Zhao X, Ding G, et al
    Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors.
    Ann Hematol. 2025;104:4201-4211.
    >> Share

  110. HERLING M, Angelucci E, Benoit TM, Rivoli G, et al
    Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.
    Ann Hematol. 2025;104:4121-4131.
    >> Share

  111. WANG Y, Zhang Y, Liu J, Jiang Y, et al
    Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges.
    Ann Hematol. 2025;104:3929-3941.
    >> Share

  112. BUCHRITS S, Trieman G, Giladi O, Hofstetter L, et al
    Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.
    Ann Hematol. 2025;104:3903-3915.
    >> Share

  113. ERNST J, Reinsch S, Mentzel HJ, Milde T, et al
    Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease.
    Ann Hematol. 2025;104:4237-4243.
    >> Share

  114. CIMINO G, Caridi M, Cardinali V, Sciabolacci S, et al
    Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.
    Ann Hematol. 2025;104:4267-4271.
    >> Share

    July 2025
  115. PARK H, Kim HJ, Sohn SK, Baik Y, et al
    Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.
    Ann Hematol. 2025 Jul 31. doi: 10.1007/s00277-025-06514.
    >> Share

  116. LAZAR DR, Maniu D, Lazar FL, Blag C, et al
    Exploring the baseline cardiac function and its correlation with risk stratification in children diagnosed with acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06523.
    >> Share

  117. QUINQUENEL A, Lepretre S, Dilhuydy MS, Bussot L, et al
    Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06498.
    >> Share

  118. HUANG L, Shi X, Tang N, Liu J, et al
    Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06499.
    >> Share

  119. BUONACQUISTO A, Del Principe MI, Pallotti F, Bianchini S, et al
    Semen quality in acute leukemia patients: a retrospective study.
    Ann Hematol. 2025 Jul 25. doi: 10.1007/s00277-025-06426.
    >> Share

  120. LIU B, Yu T, Zhou N, Yi S, et al
    Biphenotypic NK-Large granular lymphocytic leukemia with aggressive clinical features: a case report and literature review.
    Ann Hematol. 2025 Jul 23. doi: 10.1007/s00277-025-06492.
    >> Share

  121. LOPEZ-FERNANDEZ E, de Linares-Fernandez S, Perez-Marfil MN, Rodriguez-Fernandez A, et al
    Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.
    Ann Hematol. 2025 Jul 22. doi: 10.1007/s00277-025-06516.
    >> Share

  122. LIU D, Chen J, Luo Y, Yan S, et al
    Clinical features and fusion gene analysis of two Torque Teno Mini virus associated acute promyelocytic leukemia cases.
    Ann Hematol. 2025 Jul 18. doi: 10.1007/s00277-025-06501.
    >> Share

  123. CHEN C, Huang Y, Wang L, Zhang L, et al
    Prognostic significance of angiogenesis-associated molecules and Immunologic characteristic in elderly patients with acute myeloid leukemia.
    Ann Hematol. 2025 Jul 17. doi: 10.1007/s00277-025-06454.
    >> Share

  124. CHENG T, Peng J, Liu Y, Yang S, et al
    Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jul 11. doi: 10.1007/s00277-025-06471.
    >> Share

  125. ZHANG D, Li Y, Liu T, Liu X, et al
    Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2025 Jul 8. doi: 10.1007/s00277-025-06495.
    >> Share

  126. ZIELINSKA P, Gruenpeter K, Wieczorkiewicz-Kabut A, Bialas K, et al
    Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking?
    Ann Hematol. 2025 Jul 3. doi: 10.1007/s00277-025-06468.
    >> Share

  127. IZUMI A, Tachibana T, Nukui J, Miyazaki T, et al
    Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2025 Jul 3. doi: 10.1007/s00277-025-06470.
    >> Share

  128. CHEN X, Yuan L, Ma X, Wang F, et al
    TRAF3IP3::FGFR1: a novel FGFR1 fusion identified in an aggressive case of acute myeloid leukemia.
    Ann Hematol. 2025 Jul 1. doi: 10.1007/s00277-025-06494.
    >> Share

  129. KRETSCHMER L, Ruhnke L, Schliemann C, Fransecky L, et al
    VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
    Ann Hematol. 2025;104:3647-3654.
    >> Share

  130. RUBIO MA, Cisa-Wieczorek S, Mozos A, Castellet H, et al
    SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions.
    Ann Hematol. 2025;104:3655-3667.
    >> Share

  131. MARAGLINO AME, Sammassimo S, Lolli G, Clemente A, et al
    Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.
    Ann Hematol. 2025;104:3875-3879.
    >> Share

    June 2025
  132. CHEN X, Ren Y, Jin Y, Li X, et al
    First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.
    Ann Hematol. 2025 Jun 30. doi: 10.1007/s00277-025-06481.
    >> Share

  133. GETZ TM, Bakirhan K, Seropian S, Shallis RM, et al
    Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.
    Ann Hematol. 2025 Jun 27. doi: 10.1007/s00277-025-06388.
    >> Share

  134. GIAMMARCO S, Chiusolo P, Metafuni E, Limongiello MA, et al
    Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center.
    Ann Hematol. 2025 Jun 23. doi: 10.1007/s00277-025-06462.
    >> Share

  135. LI X, Wang H, Han H, Qi J, et al
    Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study.
    Ann Hematol. 2025 Jun 21. doi: 10.1007/s00277-025-06451.
    >> Share

  136. CARDINALI V, Coiro S, Martelli MP, Sportoletti P, et al
    Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome.
    Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06457.
    >> Share

  137. CAO S, Cao C, Wang S
    Efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in aggressive NK-cell leukemia: a meta-analysis.
    Ann Hematol. 2025 Jun 5. doi: 10.1007/s00277-025-06423.
    >> Share

  138. TANG J, Sun J, Liao J, Pu C, et al
    Down-regulation of circMUC16 inhibited the progression of ALL via interaction with miR-1182 and TPPP3.
    Ann Hematol. 2025;104:3389-3401.
    >> Share

  139. NACHTKAMP K, Schulz F, Kasprzak A, Strupp C, et al
    Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS).
    Ann Hematol. 2025;104:3251-3259.
    >> Share

  140. ZHOU EM, Tang Y, Liao C, Lin S, et al
    Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease.
    Ann Hematol. 2025;104:3495-3504.
    >> Share

  141. WANG T, Zhao L, Ma H
    Impact of secondary-type mutations on the prognosis of AML patients with NPM1 mutation: a systematic review and meta-analysis.
    Ann Hematol. 2025;104:3103-3115.
    >> Share

  142. CHEUNG CYM, Ha CY, Kho B, Lau CK, et al
    Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation.
    Ann Hematol. 2025;104:3091-3101.
    >> Share

    May 2025
  143. SUN K, Shi ZY, Wang YZ, Xie DH, et al
    The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.
    Ann Hematol. 2025 May 27. doi: 10.1007/s00277-025-06418.
    >> Share

  144. TRAN QUANG V, Cretin J, Loyaux R, Ben Jedidia B, et al
    Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia.
    Ann Hematol. 2025 May 24. doi: 10.1007/s00277-025-06417.
    >> Share

  145. FIANCHI L, Piciocchi A, Guolo F, Marchesi F, et al
    Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.
    Ann Hematol. 2025 May 24. doi: 10.1007/s00277-025-06381.
    >> Share

  146. PARK S, Kim HK
    Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large granular lymphocyte leukemia in Korea.
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06406.
    >> Share

  147. LIN J, Liu X, Ying S, Zhu Y, et al
    Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06399.
    >> Share

  148. GRIMALDI F, Memoli M, Avilia S, Russo R, et al
    Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary r
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06404.
    >> Share

  149. ZHU T, Wang L, Jiang H, Huang S, et al
    Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study.
    Ann Hematol. 2025 May 20. doi: 10.1007/s00277-025-06389.
    >> Share

  150. LEWANDOWSKI K, Janicki M, Baranska M, Kandula Z, et al
    Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
    Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06385.
    >> Share

  151. CECCHI N, Sciume M, Ricchiuti A, Bosi A, et al
    Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20.
    Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06332.
    >> Share

  152. SAMMARTANO V, Sicuranza A, Pacelli P, Bestoso E, et al
    Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia.
    Ann Hematol. 2025 May 15. doi: 10.1007/s00277-025-06401.
    >> Share

  153. AVAL OS, Ahmadi A, Hemid Al-Athari AJ, Soleimani Samarkhazan H, et al
    "Galectin-9: A double-edged sword in Acute Myeloid Leukemia".
    Ann Hematol. 2025 May 9. doi: 10.1007/s00277-025-06387.
    >> Share

  154. YOKOYAMA H, Fuji S, Murata M, Hirayama M, et al
    Impact of graft-versus-host disease on outcomes of cord blood transplantation according to HLA disparity and its prophylaxis type.
    Ann Hematol. 2025;104:2905-2913.
    >> Share

  155. TURKINA A, Vinogradova O, Lomaia E, Shatokhina E, et al
    Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.
    Ann Hematol. 2025;104:2707-2715.
    >> Share

  156. LIU J, Guo D, Lian H, Ding P, et al
    Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.
    Ann Hematol. 2025;104:2915-2926.
    >> Share

  157. MIAO L, Wang X, Yao M, Tao Y, et al
    Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.
    Ann Hematol. 2025;104:2581-2591.
    >> Share

  158. AN N, Bian K, Li C
    Alemtuzumab for haematological malignancies.
    Ann Hematol. 2025;104:2593-2603.
    >> Share

  159. STUCKEY R, Navarrete Bullon L, Borrero Borrego A, Vidal Ballester V, et al
    Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.
    Ann Hematol. 2025;104:3007-3009.
    >> Share

  160. YANG X, Duan Y, Zhou C, Zhang N, et al
    A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges.
    Ann Hematol. 2025;104:3059-3066.
    >> Share

  161. GARCIA M, Croizier C, Lazarian G, Quinquenel A, et al
    Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
    Ann Hematol. 2025;104:2889-2895.
    >> Share

    April 2025
  162. STOCK CN, Chillon CJ, Hernandez CL, Moro FM, et al
    Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia.
    Ann Hematol. 2025 Apr 25. doi: 10.1007/s00277-025-06325.
    >> Share

  163. MAHADEVIA H, Ponvilawan B, Shrestha A
    Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials.
    Ann Hematol. 2025 Apr 24. doi: 10.1007/s00277-025-06373.
    >> Share

  164. LIU X, Chai X, Yu Q, Wang W, et al
    Clinical features and outcomes in large granular lymphocyte leukemia - associated pure red cell aplasia with STAT3 mutation.
    Ann Hematol. 2025 Apr 23. doi: 10.1007/s00277-025-06371.
    >> Share

  165. WANG Y, Liu Q, Xu CL, Huang DP, et al
    Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.
    Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06351.
    >> Share

  166. ZHOU Y, Zhang H, Zheng X, Zhang R, et al
    Impact of BCOR/BCORL1 mutation on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients.
    Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06346.
    >> Share

  167. PATRA PC, Rainchwar S, Singh R, Bhatia N, et al
    Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India.
    Ann Hematol. 2025;104:2483-2493.
    >> Share

  168. FUJI S, Tokunaga M, Utsunomiya A, Makiyama J, et al
    Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groups.
    Ann Hematol. 2025;104:2429-2436.
    >> Share

    March 2025
  169. AN R, Bao W, Yan Z, Sun H, et al
    Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.
    Ann Hematol. 2025 Mar 31. doi: 10.1007/s00277-025-06310.
    >> Share

  170. JAMIL A, Aslam S, Riaz R, Qureshi Z, et al
    Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis.
    Ann Hematol. 2025 Mar 29. doi: 10.1007/s00277-025-06280.
    >> Share

  171. YANG K, Yang B, Zhou Y, Huang Q, et al
    Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia.
    Ann Hematol. 2025 Mar 18. doi: 10.1007/s00277-025-06312.
    >> Share

  172. MIRAZIMI Y, Aghayan AH, Atashi A, Mohammadi D, et al
    Prognostic value of circular RNAs expression and their correlation with clinicopathological features in acute myeloid leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Mar 15. doi: 10.1007/s00277-025-06300.
    >> Share

  173. ZHANG L, Lu Y, Jiang J, Wu G, et al
    Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.
    Ann Hematol. 2025 Mar 14. doi: 10.1007/s00277-025-06301.
    >> Share

  174. JIANG B, Li J, Liu L, Du X, et al
    Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.
    Ann Hematol. 2025 Mar 10. doi: 10.1007/s00277-025-06235.
    >> Share

  175. GUTIERREZ DE MORAES PEREIRA GB, Rocha VA, Barbosa PVR, Cralcev C, et al
    Twin pregnancy during treatment with asciminib for chronic myeloid leukemia - a case report.
    Ann Hematol. 2025 Mar 8. doi: 10.1007/s00277-025-06238.
    >> Share

  176. SONG BQ, Kong X, Liu Y, Pu Y, et al
    Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML.
    Ann Hematol. 2025;104:1617-1622.
    >> Share

  177. NIYONIZEYE E, Wang X, Yan D, Richard SA, et al
    Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.
    Ann Hematol. 2025;104:1807-1819.
    >> Share

  178. PAN H, Gao Z, Lian Y, Zhao J, et al
    Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.
    Ann Hematol. 2025;104:1597-1604.
    >> Share

  179. MENG M, Feng X, Zhang Y, Gao Y, et al
    Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma.
    Ann Hematol. 2025;104:1747-1756.
    >> Share

  180. MOUSAVI S, Nouri S, Sadeghipour A, Atashi A, et al
    Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.
    Ann Hematol. 2025;104:1367-1386.
    >> Share

  181. LEE BJ
    Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm.
    Ann Hematol. 2025;104:2069-2071.
    >> Share

  182. HUANG G, Cai X, Li D
    Significance of targeting DNMT3A mutations in AML.
    Ann Hematol. 2025;104:1399-1414.
    >> Share

    February 2025
  183. HORNAK T, Zackova D, Mayer J
    Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib.
    Ann Hematol. 2025 Feb 28. doi: 10.1007/s00277-025-06228.
    >> Share

  184. FANG Y, Zhao M, Luo T, Cui J, et al
    Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram.
    Ann Hematol. 2025 Feb 18. doi: 10.1007/s00277-025-06248.
    >> Share

  185. HAO L, Yao Y, Yang L
    Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.
    Ann Hematol. 2025 Feb 18. doi: 10.1007/s00277-025-06251.
    >> Share

  186. IBERTI M, Loschi M, Keslair F, Deckert M, et al
    Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesis.
    Ann Hematol. 2025 Feb 9. doi: 10.1007/s00277-025-06217.
    >> Share

  187. IYAMA S, Chi S, Idogawa M, Ikezoe T, et al
    Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.
    Ann Hematol. 2025 Feb 8. doi: 10.1007/s00277-025-06227.
    >> Share

  188. SHUMILOV E, Mazzeo P, Trautmann M, Levien L, et al
    Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia.
    Ann Hematol. 2025 Feb 6. doi: 10.1007/s00277-025-06230.
    >> Share

  189. SHAFIEIZADEGAN S, Aberuyi N, Rahgozar S
    The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53.
    Ann Hematol. 2025 Feb 5. doi: 10.1007/s00277-024-06181.
    >> Share

  190. CULLOT G, Lagarde V, Cayuela JM, Prouzet-Mauleon V, et al
    Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
    Ann Hematol. 2025;104:1117-1126.
    >> Share

  191. LIN L, Yang KH, Chen CC, Shen SH, et al
    Risk factors and a prediction model of severe asparaginase-associated pancreatitis in children.
    Ann Hematol. 2025;104:1015-1022.
    >> Share

  192. SOLANA-ALTABELLA A, Rodriguez-Veiga R, Martinez-Cuadron D, Montesinos P, et al
    A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
    Ann Hematol. 2025;104:913-935.
    >> Share

    January 2025
  193. YIGIT KAYA S, Vatani M, Akil R, Cakir T, et al
    A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06118.
    >> Share

  194. ZHENG J, Zhou Y, Zhao Y, Luo Y, et al
    Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogene
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-025-06202.
    >> Share

  195. HIDALGO-GOMEZ G, Tazon-Vega B, Palacio C, Saumell S, et al
    How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06151.
    >> Share

  196. MASUDA Y, Sadato D, Toya T, Hirama C, et al
    Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2025 Jan 22. doi: 10.1007/s00277-025-06222.
    >> Share

  197. YE Y, Zhao Z, Mo W, Liu W, et al
    Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment.
    Ann Hematol. 2025 Jan 21. doi: 10.1007/s00277-024-06169.
    >> Share

  198. SOSSA-MELO C, Abello-Polo V, Salazar LA, Pena AM, et al
    Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study.
    Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-024-06120.
    >> Share

  199. KONG J, Zheng FM, Yan CH, Wang JZ, et al
    Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-025-06198.
    >> Share

  200. SCHULZ F, Roggenbuck C, Kundgen A, Kasprzak A, et al
    Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
    Ann Hematol. 2025 Jan 11. doi: 10.1007/s00277-025-06196.
    >> Share

  201. SHAKEEL L, Khaliq N, Shaukat A, Khan A, et al
    The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06121.
    >> Share

  202. YOUSEFI A, Levin MD, Cornelissen JJ, Westerweel PE, et al
    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06170.
    >> Share

  203. JIMBO K, Ishigaki T, Sakashita M, Andoh S, et al
    Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-025-06186.
    >> Share

  204. YU S, Yang S, Hu L, Duan W, et al
    Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06182.
    >> Share

  205. JIN S, Chang M, Feng L, Hao Y, et al
    PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-025-06183.
    >> Share

  206. BUZZATTI E, Botti C, Presicci R, Mauro C, et al
    A fatal case of peritonitis due to colonic localization of acute myeloid leukemia.
    Ann Hematol. 2025 Jan 7. doi: 10.1007/s00277-024-06172.
    >> Share

  207. OH YE, Min GJ, Jeon YW, Kim TY, et al
    Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naive patients with hairy cell leukemia.
    Ann Hematol. 2025 Jan 4. doi: 10.1007/s00277-024-06173.
    >> Share

  208. MAFFEI R, Paolini A, Conte B, Riva G, et al
    Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia.
    Ann Hematol. 2025;104:263-274.
    >> Share

  209. HUANG N, Song Y, Wu L, He Q, et al
    Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.
    Ann Hematol. 2025;104:193-206.
    >> Share

  210. HOSOBA R, Fukuhara S, Kogure Y, Takano K, et al
    Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene.
    Ann Hematol. 2025;104:809-813.
    >> Share

  211. HULS G, Chitu DA, Tick L, Boersma R, et al
    Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
    Ann Hematol. 2025;104:361-368.
    >> Share

  212. GIELIS S, Flumens D, van der Heijden S, Versteven M, et al
    Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed.
    Ann Hematol. 2025;104:317-333.
    >> Share

    December 2024
  213. LIU Q, Zhao J, Li Y, Jia Y, et al
    Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis.
    Ann Hematol. 2024 Dec 28. doi: 10.1007/s00277-024-06136.
    >> Share

  214. ZHAO Y, Yu X, Yan L, Shi D, et al
    Study on clinical features of early death in older patients with acute promyelocytic leukemia.
    Ann Hematol. 2024 Dec 27. doi: 10.1007/s00277-024-06165.
    >> Share

  215. SUGIHARA A, Kubota Y, Nagaie T, Fujita M, et al
    Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
    Ann Hematol. 2024 Dec 21. doi: 10.1007/s00277-024-06153.
    >> Share

  216. MA JF, Yan CL, Jia X, Zhu HJ, et al
    Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132.
    >> Share

  217. TANG X, Liu S, Hu Y, Chen F, et al
    Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry.
    Ann Hematol. 2024 Dec 13. doi: 10.1007/s00277-024-06126.
    >> Share

  218. LI W, Ma R, Fan X, Xiao Z, et al
    M1 macrophage-derived exosomes alleviate leukemia by causing mitochondrial dysfunction.
    Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06138.
    >> Share

  219. SANCHEZ-MENDOZA SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, et al
    All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations.
    Ann Hematol. 2024 Dec 11. doi: 10.1007/s00277-024-06089.
    >> Share

  220. CHANSWANGPHUWANA C, Sukswai N, Tangnuntachai N, Rojnuckarin P, et al
    Survival impact of hypoxia-inducible factor-1 alpha (HIF-1alpha) in Nucleophosmin1 mutated acute myeloid leukemia.
    Ann Hematol. 2024 Dec 4. doi: 10.1007/s00277-024-06124.
    >> Share

  221. MATSUKAWA T, Onozawa M, Kondo T, Kanaya M, et al
    FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
    Ann Hematol. 2024;103:5333-5340.
    >> Share

  222. TAUVERON-JALENQUES U, Sarr K, Guieze R, Giordano C, et al
    Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.
    Ann Hematol. 2024;103:5985-5988.
    >> Share

  223. BIN T, Tang J, Lu B, Xu XJ, et al
    Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.
    Ann Hematol. 2024;103:5297-5314.
    >> Share

  224. KOUIDRI K, Acker F, Toenges R, Pfaff S, et al
    Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.
    Ann Hematol. 2024;103:5387-5393.
    >> Share

  225. CUI K, Zhang S, Wang Q, Wei Y, et al
    Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:5769-5780.
    >> Share

  226. PUZO CJ, Hager KM, Rinder HM, Weinberg OK, et al
    Overall survival in TP53-mutated AML and MDS.
    Ann Hematol. 2024;103:5359-5369.
    >> Share

  227. LEE BJ, Griffin SP, Doh J, Ciurea SO, et al
    Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
    Ann Hematol. 2024;103:5395-5403.
    >> Share

  228. SUN Y, Wang Q, Zhang Z, Wang Q, et al
    Distinct clinical profiles and patient outcomes in aCML and CNL.
    Ann Hematol. 2024;103:5325-5332.
    >> Share

  229. HAN X, Liu W, Kang Z, Li D, et al
    Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis.
    Ann Hematol. 2024;103:4943-4952.
    >> Share

  230. JAFARI PA, Bagheri R, Lavasani S, Goudarzi S, et al
    DNMT3A-R882: a mutation with many paradoxes.
    Ann Hematol. 2024;103:4981-4988.
    >> Share

    November 2024
  231. BERNARDI S, Cavalleri A, Mutti S, Garuffo L, et al
    Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
    Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06100.
    >> Share

  232. LI J, Chen J, Wang Q, Ou J, et al
    Clonal evolution defines risk stratification for central nervous system leukemia in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06116.
    >> Share

  233. ZHA C, Yang X, Yang J, Zhang Y, et al
    Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.
    Ann Hematol. 2024 Nov 28. doi: 10.1007/s00277-024-06117.
    >> Share

  234. LI Y, Zhang Q, Shao H
    Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Nov 27. doi: 10.1007/s00277-024-06114.
    >> Share

  235. ABDELFATTAH NE, Elsayed GM, Soliman AH, Ebeid EN, et al
    Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients' outcome.
    Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06102.
    >> Share

  236. MA H, Du Y, Li J, Rao J, et al
    Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study.
    Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06097.
    >> Share

  237. HE Y, Ding J, Liu L, Chen J, et al
    Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia.
    Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06099.
    >> Share

  238. CHEN X, Ma X, Yuan L, Wang F, et al
    The second adult case of NUTM1 fusion-positive B-cell lymphoblastic leukemia: A recurring pattern of poor prognosis.
    Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06115.
    >> Share

  239. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
    Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
    Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06095.
    >> Share

  240. BLANKSTEIN AR, Choi N, Mozessohn L, Sanford D, et al
    Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists.
    Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06085.
    >> Share

  241. MIZUNO S, Hosoi H, Takami A, Kawata T, et al
    Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2024 Nov 19. doi: 10.1007/s00277-024-06094.
    >> Share

  242. AU WY, Chow C, To KF, Ma ESK, et al
    Mixed-phenotype leukemia with TCF3::ZNF384 fusion presenting as an isolated mediastinal mass.
    Ann Hematol. 2024 Nov 12. doi: 10.1007/s00277-024-06042.
    >> Share

  243. TOLOZA MJ, Lincango M, Camacho MF, Ledesma MM, et al
    Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.
    Ann Hematol. 2024 Nov 7. doi: 10.1007/s00277-024-06074.
    >> Share

  244. MONSEREENUSORN C, Techavichit P, Sathitsamitphong L, Lertvivatpong N, et al
    Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06068.
    >> Share

  245. HUANG N, Chang C, Wu L, He Q, et al
    Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype.
    Ann Hematol. 2024;103:4485-4495.
    >> Share

  246. SPATH C, Neumann T, Kruger WH
    Antileukaemic rescue by dose-dense donor-lymphocyte infusions in T-PLL after allogeneic stem cell transplantation - a case report.
    Ann Hematol. 2024;103:4777-4778.
    >> Share

    October 2024
  247. ZHENG S, Tong Y, Yang L, Chen J, et al
    The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.
    Ann Hematol. 2024 Oct 29. doi: 10.1007/s00277-024-06050.
    >> Share

  248. FORGHIERI F, Bettelli F, Sgromo S, Nadali G, et al
    Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.
    Ann Hematol. 2024 Oct 28. doi: 10.1007/s00277-024-06047.
    >> Share

  249. MCCLELLAN K, Messina J, Saullo J, Huggins J, et al
    Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation.
    Ann Hematol. 2024 Oct 27. doi: 10.1007/s00277-024-06069.
    >> Share

  250. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
    Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
    Ann Hematol. 2024 Oct 25. doi: 10.1007/s00277-024-06048.
    >> Share

  251. EFFICACE F, Sparano F, Breccia M, Greco C, et al
    Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.
    Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06038.
    >> Share

  252. LI S, Gao R, Han X, Wang K, et al
    MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway.
    Ann Hematol. 2024 Oct 21. doi: 10.1007/s00277-024-06043.
    >> Share

  253. TRIPATHI S, K V VB, Nayak AR, Chauhan R, et al
    Ischemic stroke as a presenting feature of promyelocytic blast phase in chronic myeloid leukemia - an uncommon presentation: a case report and literature review in the post imatinib era.
    Ann Hematol. 2024 Oct 16. doi: 10.1007/s00277-024-06044.
    >> Share

  254. SCALZULLI E, Costa A, Carmosino I, Musiu P, et al
    Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time.
    Ann Hematol. 2024 Oct 15. doi: 10.1007/s00277-024-06014.
    >> Share

  255. ZHU Y, Huang J, Wang Y, Han Y, et al
    Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2024 Oct 14. doi: 10.1007/s00277-024-06027.
    >> Share

  256. YANG L, Ma D, Liu S, Zou L, et al
    The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Oct 8. doi: 10.1007/s00277-024-05998.
    >> Share

  257. WERY AR, Salaroli A, Andreozzi F, Paesmans M, et al
    Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study.
    Ann Hematol. 2024 Oct 4. doi: 10.1007/s00277-024-06017.
    >> Share

  258. LI HD, Chen SS, Ding J, Zhang CL, et al
    Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.
    Ann Hematol. 2024;103:4295-4304.
    >> Share

  259. CHEN CY
    Chromothripsis in myeloid malignancies.
    Ann Hematol. 2024;103:3955-3962.
    >> Share

  260. GAO Y, Xi Y, Chen W, Meng Y, et al
    Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide.
    Ann Hematol. 2024;103:3947-3954.
    >> Share

  261. GE S, Wang J, He Q, Zhu J, et al
    Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.
    Ann Hematol. 2024;103:3855-3866.
    >> Share

    September 2024
  262. PAN YS, Li H, Yang M, Zhang CL, et al
    A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype.
    Ann Hematol. 2024 Sep 30. doi: 10.1007/s00277-024-06030.
    >> Share

  263. AHMAD F, Shah A, Angi M, Narmawala Q, et al
    Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report.
    Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05966.
    >> Share

  264. HAGIHARA M, Yasu T, Gando Y, Sugi T, et al
    Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.
    Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05845.
    >> Share

  265. KRAMP LJ, Heydrich-Karsten C, Sembill S, Karow A, et al
    CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
    Ann Hematol. 2024 Sep 21. doi: 10.1007/s00277-024-06011.
    >> Share

  266. DUAN W, Jia J, Wang J, Liu X, et al
    Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.
    Ann Hematol. 2024 Sep 17. doi: 10.1007/s00277-024-06001.
    >> Share

  267. ZHAO Z, Lan J
    Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.
    Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06008.
    >> Share

  268. YANG S, Huang H, Zhou K, Zhao X, et al
    Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.
    Ann Hematol. 2024 Sep 14. doi: 10.1007/s00277-024-05978.
    >> Share

  269. PEREZ-LAMAS L, Diaz AS, Castera EM, Soto MH, et al
    Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
    Ann Hematol. 2024 Sep 13. doi: 10.1007/s00277-024-05906.
    >> Share

  270. ATNAF A, Akelew Y, Abebaw D, Muche Y, et al
    The role of long noncoding RNAs in the diagnosis, prognosis and therapeutic biomarkers of acute myeloid leukemia.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05987.
    >> Share

  271. HAN P, Wei S, Wang H, Cai Y, et al
    Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-06003.
    >> Share

  272. SIFFEL C, Richter J, Anderson-Smits C, Kamieniak M, et al
    Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05984.
    >> Share

  273. JAIN AG, Volpe VO, Wang C, Ball S, et al
    Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
    Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05976.
    >> Share

  274. WEI Y, Qian K, Le N, Wang L, et al
    Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
    Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05972.
    >> Share

  275. STEINER N, Baier K, Ritter D, Rudzki J, et al
    Early autologous and/or allogeneic stem cell transplantation for adult patients with advanced stage T- lymphoblastic leukemia/lymphoma or Burkitt lymphoma. A retrospective single-centre analysis.
    Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05979.
    >> Share

  276. TALEBI E, Ghoraeian P, Shams Z, Rahimi H, et al
    Molecular insights into the hedgehog signaling pathway correlated non-coding RNAs in acute lymphoblastic leukemia, a bioinformatics study.
    Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05763.
    >> Share

  277. SOBAS M, Ianotto JC, Kiladjian JJ, Harrison C, et al
    Myeloproliferative neoplasms: young patients, current data and future considerations.
    Ann Hematol. 2024;103:3287-3291.
    >> Share

  278. GUARNERA L, Tiravanti I, Guiducci A, Coppola L, et al
    Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.
    Ann Hematol. 2024;103:3831-3833.
    >> Share

  279. HUA W, Qi J, Zhou M, Han S, et al
    Overexpression of REC8 induces aberrant gamete meiotic division and contributes to AML pathogenesis - a multiplexed microarray analysis and mendelian randomization study.
    Ann Hematol. 2024;103:3563-3572.
    >> Share

  280. COX ER, Summers C, Milano F, Dahlberg A, et al
    Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies.
    Ann Hematol. 2024;103:3737-3743.
    >> Share

  281. CHEN F
    ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with blast crisis treated with flumatinib mesylate.
    Ann Hematol. 2024;103:3801-3804.
    >> Share

  282. ROZENTAL A, Halperin E, Leibovitch C, Barzili M, et al
    CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study.
    Ann Hematol. 2024;103:3585-3594.
    >> Share

  283. HU L, Li Z, Yang S, Zhao T, et al
    Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Ann Hematol. 2024;103:3745-3754.
    >> Share

  284. YANG M, Tang Y, Zhu P, Lu H, et al
    The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia.
    Ann Hematol. 2024;103:3385-3398.
    >> Share

  285. WEI Z, Su L, Gao S
    The roles of ubiquitination in AML.
    Ann Hematol. 2024;103:3413-3428.
    >> Share

    August 2024
  286. XU Q, Li H, Huang P, Lin W, et al
    Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period-a retrospective study in two medical centers.
    Ann Hematol. 2024 Aug 31. doi: 10.1007/s00277-024-05939.
    >> Share

  287. JIMENEZ-VICENTE C, Guardia-Torrelles A, Perez-Valencia AI, Martinez-Roca A, et al
    Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05923.
    >> Share

  288. KLOS C, Roynard P, Berthon C, Soenen V, et al
    Unravelling a KMT2A::ARHGEF12 fusion within chromoanagenesis in acute myeloid leukemia using Optical Genome Mapping.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05948.
    >> Share

  289. PRAJAPATI SK, Kumari N, Bhowmik D, Gupta R, et al
    Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05963.
    >> Share

  290. SOLIS-ARMENTA R, Rodriguez-Rodriguez S, Hernandez-Perez AP, Paulina-Zapata N, et al
    Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.
    Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05956.
    >> Share

  291. BADER MS, Kubetzko S, Schafer BW, Arranto C, et al
    Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05943.
    >> Share

  292. MENG Z, Zheng H, Liu Y, Guo X, et al
    Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05667.
    >> Share

  293. YANG Y, Wang L, Peng Y, Nie X, et al
    Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05954.
    >> Share

  294. SUGITA J, Morita K, Konuma T, Yanada M, et al
    Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.
    Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05944.
    >> Share

  295. NUNES RAB, Avezum A, de Oliveira Marques M, Baiocchi OCCG, et al
    Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05921.
    >> Share

  296. TARANTINI F, Cumbo C, Parciante E, Anelli L, et al
    IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms.
    Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05938.
    >> Share

  297. YAO Y, Zhou J, Li Y, Shi S, et al
    CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05945.
    >> Share

  298. SU Z, Cong B, Dong P
    A novel FNDC3B::MECOM fusion gene accompanied with Der(5; 17)(p10; q10) in acute myelocytic leukemia.
    Ann Hematol. 2024 Aug 14. doi: 10.1007/s00277-024-05930.
    >> Share

  299. LAU C, van Kesteren C, Cao YX, Smeenk RM, et al
    Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.
    Ann Hematol. 2024 Aug 12. doi: 10.1007/s00277-024-05924.
    >> Share

  300. FORGHIERI F, Cordella S, Marchesi F, Itri F, et al
    Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemi
    Ann Hematol. 2024 Aug 8. doi: 10.1007/s00277-024-05927.
    >> Share

  301. WANG SX, Wang F, Tu YC, Zhou YL, et al
    Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review.
    Ann Hematol. 2024 Aug 6. doi: 10.1007/s00277-024-05759.
    >> Share

  302. TAMELLINI E, Simio C, Bernardelli A, Ferrarini I, et al
    Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.
    Ann Hematol. 2024 Aug 3. doi: 10.1007/s00277-024-05922.
    >> Share

  303. GUO W, Zhang H, Wang M, Zheng Y, et al
    WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients.
    Ann Hematol. 2024;103:2827-2836.
    >> Share

  304. CHOQUET S, Marchal C, Deygas F, Deslandes M, et al
    A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
    Ann Hematol. 2024;103:2969-2981.
    >> Share

  305. GUO W, Zhang H, Zheng Y, Gao H, et al
    Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT.
    Ann Hematol. 2024;103:3155-3163.
    >> Share

  306. SUAREZ EU, Boluda B, Lavilla E, Tormo M, et al
    Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
    Ann Hematol. 2024;103:2845-2851.
    >> Share

  307. SHI H, Yang F, Cao M, Xu T, et al
    Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
    Ann Hematol. 2024;103:2993-3004.
    >> Share

  308. KT MF, Semwal M, Yoosuf BT, Lad D, et al
    Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS.
    Ann Hematol. 2024;103:3179-3191.
    >> Share

  309. HU R, Liao P, Xu B, Qiu Y, et al
    N6-methyladenosine RNA modifications: a potential therapeutic target for AML.
    Ann Hematol. 2024;103:2601-2612.
    >> Share

    July 2024
  310. DENG J, Qin X, Ma G, Shen X, et al
    Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
    Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05862.
    >> Share

  311. FAN BE, Chow M
    Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models.
    Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05916.
    >> Share

  312. ROBAK T, Pula A, Braun M, Robak E, et al
    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.
    Ann Hematol. 2024 Jul 25. doi: 10.1007/s00277-024-05854.
    >> Share

  313. DAI Y, Luo L, Wei Z, Cheng P, et al
    The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
    Ann Hematol. 2024 Jul 24. doi: 10.1007/s00277-024-05892.
    >> Share

  314. LIPTON JH, Brummendorf TH, Sweet K, Apperley JF, et al
    Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.
    Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05851.
    >> Share

  315. ZHAO Y, Huang Y, Jiang L, Zhang Y, et al
    Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
    Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05884.
    >> Share

  316. KONTANDREOPOULOU CN, Solomou EE, Kolorizos E, Diamantopoulos PT, et al
    Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Jul 15. doi: 10.1007/s00277-024-05869.
    >> Share

  317. CAO HY, Li HY, Cai WZ, Huang YH, et al
    Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
    Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05868.
    >> Share

  318. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
    Correction to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
    Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05881.
    >> Share

  319. LAIMON DN, Sakr DH, Atef B, Shaaban Y, et al
    Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters.
    Ann Hematol. 2024 Jul 10. doi: 10.1007/s00277-024-05861.
    >> Share

  320. SINGH S, Lionel S, Jain H, Rajendra A, et al
    Treatment challenges and outcomes of older patients with acute myeloid leukemia from India.
    Ann Hematol. 2024 Jul 8. doi: 10.1007/s00277-024-05873.
    >> Share

  321. ZHENG J, Zhao Y, Luo Y, Yu J, et al
    Impact of additional cytogenetic aberrations at diagnosis on prognosis of adults patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis.
    Ann Hematol. 2024 Jul 4. doi: 10.1007/s00277-024-05871.
    >> Share

  322. WANG J, Mu M, Zhu J, Yang J, et al
    Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria.
    Ann Hematol. 2024 Jul 3. doi: 10.1007/s00277-024-05866.
    >> Share

  323. CHEN R, Tao Q, Wu F, Zhai Z, et al
    DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL.
    Ann Hematol. 2024;103:2551-2556.
    >> Share

  324. PANDA D, Tejwani N, Pandey P, Mehta A, et al
    Myeloid sarcoma with RAM phenotype in an adult male presenting with CNS relapse; no longer a pediatric disease.
    Ann Hematol. 2024;103:2561-2563.
    >> Share

  325. CHEN Y, Chen Y, Wu Z, Li J, et al
    Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes.
    Ann Hematol. 2024;103:2393-2404.
    >> Share

    June 2024
  326. GONG Y, Li Y, Chen X, Yang H, et al
    Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.
    Ann Hematol. 2024 Jun 27. doi: 10.1007/s00277-024-05856.
    >> Share

  327. SHI Y, Chen X, Jin H, Zhu L, et al
    Correction to: Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
    Ann Hematol. 2024 Jun 24. doi: 10.1007/s00277-024-05812.
    >> Share

  328. CAO X, Li Z, Zhang Y, Cui Q, et al
    Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024 Jun 20. doi: 10.1007/s00277-024-05849.
    >> Share

  329. ZHOU K, Wang T, Pan L, Xu W, et al
    Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
    Ann Hematol. 2024 Jun 18. doi: 10.1007/s00277-024-05823.
    >> Share

  330. WANG XZ, Gao XM, Wang JM, Cai H, et al
    Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.
    Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05842.
    >> Share

  331. ABULIMITI M, Jia ZY, Wu Y, Yu J, et al
    Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.
    Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05841.
    >> Share

  332. LI T, Wu P, Wang A, Chen M, et al
    A HNRNPC::RARB variant of acute promyelocytic leukemia with concurrent myeloid sarcoma of the spine.
    Ann Hematol. 2024 Jun 12. doi: 10.1007/s00277-024-05833.
    >> Share

  333. ZHANG Z, Fu C, Sun Y, Liu Y, et al
    High hyperdiploid karyotype with >/= 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.
    Ann Hematol. 2024 Jun 8. doi: 10.1007/s00277-024-05834.
    >> Share

  334. WEI D, Liang X, Huang M, Wang C, et al
    Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.
    Ann Hematol. 2024 Jun 7. doi: 10.1007/s00277-024-05830.
    >> Share

  335. BOUCHLA A, Sotiropoulou CD, Esteb C, Loupis T, et al
    Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.
    Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05785.
    >> Share

  336. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
    Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
    Ann Hematol. 2024 Jun 5. doi: 10.1007/s00277-024-05821.
    >> Share

  337. ZHENG B, Geng Y, Li Y, Huang H, et al
    Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through beta-catenin by acting as targets of miR-495-3p.
    Ann Hematol. 2024 Jun 3. doi: 10.1007/s00277-024-05764.
    >> Share

  338. JAIN AG, Gesiotto Q, Ball S, Nodzon L, et al
    Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
    Ann Hematol. 2024;103:1941-1945.
    >> Share

    May 2024
  339. LI Y, Zhang Q, Shao H
    Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene.
    Ann Hematol. 2024 May 29. doi: 10.1007/s00277-024-05816.
    >> Share

  340. WANG Q, Hu Y, Gao L, Zhang S, et al
    Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.
    Ann Hematol. 2024 May 28. doi: 10.1007/s00277-024-05810.
    >> Share

  341. BRAUN A, Otoukesh S, Tinajero J, Marcucci G, et al
    Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL).
    Ann Hematol. 2024 May 24. doi: 10.1007/s00277-024-05795.
    >> Share

  342. IOVENE FR, Santinelli E, Armiento D, Sarlo C, et al
    Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.
    Ann Hematol. 2024 May 23. doi: 10.1007/s00277-024-05804.
    >> Share

  343. CUI T, Li H, Zhou S, Li J, et al
    Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2024 May 17. doi: 10.1007/s00277-024-05791.
    >> Share

  344. FONTECHA MB, Anadon MDR, Mercado Guzman V, Stanganelli C, et al
    Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
    Ann Hematol. 2024 May 14. doi: 10.1007/s00277-024-05794.
    >> Share

  345. TOLLE M, Gokbuget N, Habringer S, Keller U, et al
    Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
    Ann Hematol. 2024 May 11. doi: 10.1007/s00277-024-05789.
    >> Share

  346. SHI Y, Chen X, Jin H, Zhu L, et al
    Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
    Ann Hematol. 2024 May 9. doi: 10.1007/s00277-024-05786.
    >> Share

  347. MITROVIC-AJTIC O, Zivkovic E, Suboticki T, Diklic M, et al
    Inflammation mediated angiogenesis in chronic lymphocytic leukemia.
    Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05781.
    >> Share

  348. MENSHAWY NE, El-Ghonemy MS, Ebrahim MA, Fahmi MW, et al
    Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
    Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05779.
    >> Share

  349. FRANKE GN, Loewe G, Reiser M, Linde H, et al
    Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
    Ann Hematol. 2024;103:1569-1575.
    >> Share

  350. NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
    Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Ann Hematol. 2024;103:1787-1788.
    >> Share

  351. SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
    Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Ann Hematol. 2024;103:1587-1599.
    >> Share

    April 2024
  352. LIU Y, Liu Y, Chen P, Chen G, et al
    GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
    Ann Hematol. 2024 Apr 27. doi: 10.1007/s00277-024-05777.
    >> Share

  353. TAZOE K, Harada N, Makuuchi Y, Kuno M, et al
    Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05772.
    >> Share

  354. BENCHIKH S, Charlene SSG, Bousfiha A, Razoki L, et al
    Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco.
    Ann Hematol. 2024 Apr 24. doi: 10.1007/s00277-024-05747.
    >> Share

  355. THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
    COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
    Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
    >> Share

  356. JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
    Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
    Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
    >> Share

  357. LEOTTA S, Markovic U, Duminuco A, Mule A, et al
    Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
    Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
    >> Share

  358. GU Z, Li F, Li M, Wang L, et al
    Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study.
    Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
    >> Share

  359. LUO L, Jiao Y, Li Y, Yang P, et al
    Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
    Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
    >> Share

  360. PEREZ-LAMAS L, de Paz Arias R, Diaz RMA, Montero LFC, et al
    Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
    Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662.
    >> Share

  361. LIU S, Cui Q, Li M, Li Z, et al
    Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
    Ann Hematol. 2024;103:1397-1402.
    >> Share

  362. REN Y, Liu F, Chen X, Zhang X, et al
    Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1345-1351.
    >> Share

  363. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
    Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1187-1196.
    >> Share

  364. WANG J, Zhu H, Miao K
    Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05714.
    >> Share

    March 2024
  365. CHEN Y, Pan M, Chen L, Peng M, et al
    Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 27. doi: 10.1007/s00277-024-05675.
    >> Share

  366. WU CY, Yeh CM, Tsai CK, Liu CJ, et al
    The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.
    Ann Hematol. 2024 Mar 26. doi: 10.1007/s00277-024-05616.
    >> Share

  367. CAI X, Liu Y, Li H, Que Y, et al
    XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Ann Hematol. 2024 Mar 23. doi: 10.1007/s00277-024-05706.
    >> Share

  368. KUROSAWA S, Yokota T, Takada Y, Okubo S, et al
    Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
    Ann Hematol. 2024 Mar 21. doi: 10.1007/s00277-024-05721.
    >> Share

  369. HUANG XT, Wang CJ, Gao C, Xue TL, et al
    Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 18. doi: 10.1007/s00277-024-05687.
    >> Share

  370. OU J, Deng S, Ding C, Cai Z, et al
    Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681.
    >> Share

  371. RORVIK SD, Torkildsen S, Bruserud O, Tvedt THA, et al
    Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05680.
    >> Share

  372. DARTIGEAS C, Quinquenel A, Ysebaert L, Dilhuydy MS, et al
    Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666.
    >> Share

  373. WU X, Ma X, Song T, Liu J, et al
    The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.
    Ann Hematol. 2024;103:917-933.
    >> Share

  374. KENNEDY A, Patel S, Ramanathan M, Gerber J, et al
    Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
    Ann Hematol. 2024;103:1031-1033.
    >> Share

  375. KRECAK I, Cubric E, Smolic J, Vrbicic B, et al
    Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib.
    Ann Hematol. 2024;103:1021-1023.
    >> Share

  376. PALANI HK, Ganesan S, Balasundaram N, Venkatraman A, et al
    Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673.
    >> Share

    February 2024
  377. SCHWANER I, Kuhn T, Losem C, Wolff T, et al
    Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Ann Hematol. 2024 Feb 29. doi: 10.1007/s00277-024-05638.
    >> Share

  378. CHEN Y, Zheng J, Weng Y, Wu Z, et al
    Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Ann Hematol. 2024 Feb 27. doi: 10.1007/s00277-024-05679.
    >> Share

  379. TERAMOTO M, Tamaki H, Kaida K, Samori M, et al
    Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis.
    Ann Hematol. 2024 Feb 23. doi: 10.1007/s00277-024-05654.
    >> Share

  380. WANG X, Zhang Y, Xue S
    Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
    Ann Hematol. 2024 Feb 21. doi: 10.1007/s00277-023-05601.
    >> Share

  381. GOTO T, Nakamura N, Suzaki T, Shimazu R, et al
    A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
    Ann Hematol. 2024 Feb 20. doi: 10.1007/s00277-024-05660.
    >> Share

  382. LI X, Zhou J, Li J, Zhu X, et al
    Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
    Ann Hematol. 2024 Feb 17. doi: 10.1007/s00277-024-05656.
    >> Share

  383. ZHAO L, Yang J, Chen M, Xiang X, et al
    Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
    Ann Hematol. 2024 Feb 8. doi: 10.1007/s00277-024-05646.
    >> Share

  384. FONTANA D, Zambrotta GPM, Scannella A, Piazza R, et al
    Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
    Ann Hematol. 2024 Feb 7. doi: 10.1007/s00277-024-05649.
    >> Share

  385. SCHLOSSER P, Schiwitza A, Klaus J, Hieke-Schulz S, et al
    Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05627.
    >> Share

  386. SUAREZ EU, Piris MA, Rodriguez-Pinilla SM, Garcia JF, et al
    Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05647.
    >> Share

  387. WANG J, Zhang H, Zhang R
    BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.
    Ann Hematol. 2024;103:685-687.
    >> Share

  388. BRUNNER A, Thalhammer-Thurner GC, Willenbacher W, Haun M, et al
    In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
    Ann Hematol. 2024;103:553-563.
    >> Share

  389. FERNANDEZ-LUIS S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, et al
    Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
    Ann Hematol. 2024;103:583-591.
    >> Share

    January 2024
  390. CHEN Y, Pan M, Chen L, Peng M, et al
    Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05629.
    >> Share

  391. CUI J, Zhao M, Liu W, Hong M, et al
    Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05645.
    >> Share

  392. LIU Y, Ma Z
    Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.
    Ann Hematol. 2024 Jan 29. doi: 10.1007/s00277-024-05635.
    >> Share

  393. GABELLIER L, Peterlin P, Thepot S, Hicheri Y, et al
    Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Ann Hematol. 2024 Jan 26. doi: 10.1007/s00277-024-05623.
    >> Share

  394. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
    Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
    Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
    >> Share

  395. MURRU R, Galitzia A, Barabino L, Presicci R, et al
    Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
    Ann Hematol. 2024 Jan 18. doi: 10.1007/s00277-024-05625.
    >> Share

  396. ZHAO Y, Zhang X, Zhang M, Guo R, et al
    Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
    Ann Hematol. 2024 Jan 12. doi: 10.1007/s00277-024-05617.
    >> Share

  397. DEREME J, Voruz S, Solly F, Schoumans J, et al
    Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.
    Ann Hematol. 2024 Jan 9. doi: 10.1007/s00277-023-05600.
    >> Share

  398. SONG J, Li W, Bai Y, Zhou P, et al
    A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Ann Hematol. 2024 Jan 6. doi: 10.1007/s00277-023-05594.
    >> Share

  399. PERRUSO LL, Velloso E, Rocha V, Rego EM, et al
    Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2024 Jan 5. doi: 10.1007/s00277-023-05609.
    >> Share

  400. WANG R, Xu Y, Wang B, Wang H, et al
    Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
    Ann Hematol. 2024;103:61-71.
    >> Share

  401. AL BARASHDI MAS, Ali A, McMullin MF, Mills K, et al
    CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
    Ann Hematol. 2024;103:73-88.
    >> Share

    December 2023
  402. HUANG P, Chang H, Zhang R, Wu Y, et al
    Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.
    Ann Hematol. 2023 Dec 28. doi: 10.1007/s00277-023-05593.
    >> Share

  403. PAN B, Xu Z, Du K, Gao R, et al
    Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.
    Ann Hematol. 2023 Dec 27. doi: 10.1007/s00277-023-05590.
    >> Share

  404. SOBAS M, Knopinska-Posluszny W, Piatkowska-Jakubas B, Garcia-Alvarez F, et al
    Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
    Ann Hematol. 2023 Dec 19. doi: 10.1007/s00277-023-05582.
    >> Share

  405. PARK T, Byun JM, Shin DY, Koh Y, et al
    Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases.
    Ann Hematol. 2023 Dec 8. doi: 10.1007/s00277-023-05575.
    >> Share

  406. ZHENG X, Gao H, Lu N, Wang M, et al
    Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
    Ann Hematol. 2023;102:3603-3611.
    >> Share

  407. HU J, Zhao J, Wang C, Jia M, et al
    Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
    Ann Hematol. 2023;102:3593-3601.
    >> Share

  408. ANDERSEN M JR, Bindal P, Michaels P, Elavalakanar P, et al
    Clonal myeloid disorders following CAR T-cell therapy.
    Ann Hematol. 2023;102:3643-3645.
    >> Share

  409. BEWERSDORF JP, Shallis RM, Sharon E, Park S, et al
    A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
    Ann Hematol. 2023 Dec 1. doi: 10.1007/s00277-023-05552.
    >> Share

    November 2023
  410. MARRA JD, Frioni F, Minnella G, Rossi M, et al
    Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management.
    Ann Hematol. 2023 Nov 29. doi: 10.1007/s00277-023-05561.
    >> Share

  411. MULAS O, Abruzzese E, Luciano L, Iurlo A, et al
    The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Ann Hematol. 2023 Nov 28. doi: 10.1007/s00277-023-05556.
    >> Share

  412. ISHIDA H, Arakawa Y, Hasegawa D, Usami I, et al
    Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 25. doi: 10.1007/s00277-023-05557.
    >> Share

  413. FISCHER D, Toenges R, Kiil K, Michalik S, et al
    Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 24. doi: 10.1007/s00277-023-05495.
    >> Share

  414. SHANG CY, Bei LY, Wu JZ, Sheng HR, et al
    NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 23. doi: 10.1007/s00277-023-05554.
    >> Share

  415. GAO J, Han S, Deng B, Deng Y, et al
    Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05550.
    >> Share

  416. TIAN J, Wei A, Wang B, Yang J, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05506.
    >> Share

  417. LAP CJ, Abrahim MS, Nassereddine S
    Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
    Ann Hematol. 2023 Nov 17. doi: 10.1007/s00277-023-05545.
    >> Share

  418. CHEN B, Zhao Y, Xu S, Jiang F, et al
    USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
    Ann Hematol. 2023 Nov 10. doi: 10.1007/s00277-023-05522.
    >> Share

  419. LUCIJANIC M, Tomasovic-Loncaric C, Stoos-Veic T, De Both T, et al
    Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05529.
    >> Share

  420. AHMED HA, Nafady A, Ahmed EH, Hassan EEN, et al
    CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05540.
    >> Share

  421. FAN S, Wang L, Lu Y, Li Z, et al
    Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05519.
    >> Share

  422. DE OLIVEIRA FERNANDES JUNIOR I, Arcuri LJ
    Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05532.
    >> Share

  423. BABAKHANLOU R, Nader ME, Alvarado Y
    Correction to: A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05524.
    >> Share

  424. HUSSAN SS, Ali MS, Fatima M, Altaf M, et al
    Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05515.
    >> Share

  425. HUANG X, Li T, Zhang Y, Gao X, et al
    Hemophagocytosis by multinucleated leukemic blasts, basophilia, and micromegakaryocytes in AML with TLS::ERG.
    Ann Hematol. 2023;102:3279-3281.
    >> Share

  426. PERRONE S, Imperatore S, Sucato G, Notarianni E, et al
    Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.
    Ann Hematol. 2023;102:3025-3030.
    >> Share

  427. HEGDE NC, Kumar A, Kaundal S, Saha L, et al
    Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia.
    Ann Hematol. 2023;102:3125-3132.
    >> Share

    October 2023
  428. SAVANI S, Chennapragada SS, Ramphul K, Dandwani M, et al
    Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.
    Ann Hematol. 2023 Oct 27. doi: 10.1007/s00277-023-05505.
    >> Share

  429. TANG H, Chen Y, Zhang N, Deng J, et al
    Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy.
    Ann Hematol. 2023 Oct 25. doi: 10.1007/s00277-023-05516.
    >> Share

  430. CUI Y, Peng H
    Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Oct 21. doi: 10.1007/s00277-023-05489.
    >> Share

  431. FEI X, Zhang W, Gu J, Yang F, et al
    CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Ann Hematol. 2023 Oct 17. doi: 10.1007/s00277-023-05502.
    >> Share

  432. YIN S, Zheng X, Zhang W, Zhao H, et al
    Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05486.
    >> Share

  433. EISENACH S, Zinke J, Bramer D, Hartinger S, et al
    Detection of a rare JAK2(exon13InDel)-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Loffler endocarditis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05490.
    >> Share

  434. CREMER A, Enssle JC, Pfaff S, Kouidri K, et al
    Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
    Ann Hematol. 2023;102:2903-2908.
    >> Share

  435. MARTINO G, Cimino G, Caridi M, Perta G, et al
    One disease, two faces: clonally-related AML and MPDCP with skin involvement.
    Ann Hematol. 2023;102:2969-2971.
    >> Share

    September 2023
  436. XU Y, Gao H, Li H
    The gut microbiome: an important factor influencing therapy for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 29. doi: 10.1007/s00277-023-05480.
    >> Share

  437. PEREIRA MP, Herrity E, Kim DDH
    TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Ann Hematol. 2023 Sep 28. doi: 10.1007/s00277-023-05462.
    >> Share

  438. ZOU D, Lv M, Chen Y, Niu T, et al
    Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone.
    Ann Hematol. 2023 Sep 26. doi: 10.1007/s00277-023-05468.
    >> Share

  439. CANDAN O, Demirtas D, Yanik AM, Atagunduz I, et al
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05456.
    >> Share

  440. LIN Q, Ye P, Wang T, Lu Y, et al
    Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05401.
    >> Share

  441. LI H, Hou J, Fu Y, Zhao Y, et al
    miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
    Ann Hematol. 2023 Sep 19. doi: 10.1007/s00277-023-05441.
    >> Share

  442. WENG G, Huang J, He X, Xue T, et al
    Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Ann Hematol. 2023 Sep 18. doi: 10.1007/s00277-023-05452.
    >> Share

  443. BABAKHANLOU R, Ellie-Nader M, Alvarado Y
    A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Sep 15. doi: 10.1007/s00277-023-05433.
    >> Share

  444. CROUCHER PJP, Ridinger M, Becker PS, Lin TL, et al
    Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2023 Sep 13. doi: 10.1007/s00277-023-05442.
    >> Share

  445. JIANG S, Lu X, Wei R, Zhang A, et al
    Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
    Ann Hematol. 2023 Sep 8. doi: 10.1007/s00277-023-05406.
    >> Share

  446. WANG Q, Liang Z, Ren H, Dong Y, et al
    Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05429.
    >> Share

  447. LIU Y, Chen P, Chen G, Chen X, et al
    E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05431.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016